Tern Plc Tranche One of Device Authority Fund Raise Now Complete

Tern plc

Tern Plc (AIM:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has announced that, further to the Company’s announcement of 27 December 2023, Tranche One (“T1”) of the Device Authority Fund Raise has now completed.  Through T1 Device Authority has received US$4.0 million.

A further announcement will be made by Tern Plc in due course upon completion of the Second Tranche (“T2”) of the Device Authority Fund Raise. T2 totals US$3.3 million and is contingent on approval pursuant to the National Security and Investment Act 2021 (“NASI”) and acceptance of the approval by Ten Eleven Ventures.

Unless otherwise stated, defined terms should be given the meaning given to them in the announcement made on 27 December 2023.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern notes automotive momentum at Device Authority

Tern Plc notes that Device Authority, in which it holds a 25.3% stake, has announced further progress in the automotive sector, securing a new OEM customer and expanding an existing Tier 1 deployment.

Key management emerges as a delivery risk in automotive software

Key management is becoming a delivery-critical constraint in software-defined vehicles, influencing risk, compliance and programme scalability.

Pharma teams gain early insight into message effectiveness

Talking Medicines gives pharma teams early insight into which messages resonate with healthcare professionals.

Talking Medicines joins 2026 UK AI Index

Talking Medicines joins the UK AI Index 2026, confirming its growing role in data-driven healthcare strategy.

AI in Healthcare 2025

In 2025, AI began reshaping healthcare delivery and marketing with practical applications, signalling a maturing investment landscape.

Talking Medicines targets messaging risk in pharma brand strategy

Talking Medicines reduces messaging risk for pharma brands by measuring real-time HCP response.

Search

Search